Curcumin in Treating Breast Cancer: A Review

Wang, Yiwei; Yu, Junzhi; Cui, Ran; Lin, Jin-Jin; Li, Yiyang

doi:10.1177/2211068216655524

Cited by 121 publications

(71 citation statements)

References 93 publications

(99 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1], isolated from the powdered rhizome of Curcuma longa L. (Zingiberaceae) (17,18), interacts with numerous biological targets, including inflammatory mediators, growth factors, enzymes, carrier proteins, metal ions, tumor suppressors, transcription factors, oncoproteins and cellular nucleic acids (19)(20)(21). Discovered in 1815 by Vogel and Pelletier as a yellow pigment (4), curcumin has been consumed for >2,000 years in Asian countries, due to its various medicinal properties against human diseases, including cancer and auto-immune diseases (10,17,(22)(23)(24)(25)(26)(27)(28)(29).…”

Section: Introductionmentioning

confidence: 99%

Molecular targets of curcumin in breast cancer (Review)

et al. 2018

View full text Add to dashboard Cite

Curcumin (diferuloylmethane), an orange-yellow component of turmeric or curry powder, is a polyphenol natural product isolated from the rhizome of Curcuma longa. For centuries, curcumin has been used in medicinal preparations and as a food colorant. In recent years, extensive in vitro and in vivo studies have suggested that curcumin possesses activity against cancer, viral infection, arthritis, amyloid aggregation, oxidation and inflammation. Curcumin exerts anticancer effects primarily by activating apoptotic pathways in cancer cells and inhibiting pro-cancer processes, including inflammation, angiogenesis and metastasis. Curcumin targets numerous signaling pathways associated with cancer therapy, including pathways mediated by p53, Ras, phosphatidylinositol-3-kinase, protein kinase B, Wnt-β catenin and mammalian target of rapamycin. Clinical studies have demonstrated that curcumin alone or combined with other drugs exhibits promising anticancer activity in patients with breast cancer without adverse effects. In the present review, the chemistry and bioavailability of curcumin and its molecular targets in breast cancer are discussed. Future research directions are discussed to further understand this promising natural product.

show abstract

Section: Introductionmentioning

confidence: 99%

Molecular targets of curcumin in breast cancer (Review)

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In recent decades, natural products have formed an important part of drug discovery. Among these natural products, curcumin (diferuloylmethane), a hydrophobic polyphenol derived from turmeric (Curcuma longa) has been used for the treatment of numerous diseases, including cancer (9). Curcumin possesses several beneficial properties, including anti-inflammatory, anti-metastatic and anti-carcinogenic effects, as well as acting as an inhibitor of tumor formation (10,11).…”

Section: Introductionmentioning

confidence: 99%

Curcumin and paclitaxel induce cell death in breast cancer cell lines

2018

View full text Add to dashboard Cite

Breast cancer is one of the major health issues confronting women; however, treatment with conventional chemotherapeutic drugs is limited. Currently, paclitaxel is used as a therapeutic clinical agent to treat breast cancer that exerts antitumor activity in numerous types of cancer cell. Curcumin (diferuloylmethane), a polyphenol derived from turmeric (Curcuma longa), possesses several properties that could enable it to exert an anticancer effect. Previous reports have demonstrated the synergistic effects of several chemotherapeutic drugs in combination with curcumin. Therefore, the aim of the current study was to evaluate cell death induced by curcumin and paclitaxel alone and in combination in human breast cancer cell lines: MCF7, an epithelial and luminal-like adenocarcinoma cell line triple positive for estrogen and progesterone receptor, and MDA-MB-234, a metastatic human breast cancer cell line triple negative for such receptors, as well as MCF-10F as a normal breast cell line. The results indicated that curcumin and paclitaxel induced apoptosis and necrosis, which was demonstrated through multiple methods, including assays of caspase-3/7 activity, Annexin V, poly(ADP-ribose) polymerase-1 activation and protein expression of caspase-3, nuclear factor (NF)-κB transcription factor and proliferating cell nuclear antigen. The results identified that the combination of curcumin and paclitaxel had a decreased effect on apoptosis in the malignant MDA-MB-231 cell line compared with in MCF7 or MCF-10F. It was demonstrated that the combined treatment with curcumin and paclitaxel resulted in a higher level of apoptosis compared with either substance alone in breast cancer cell lines. Therefore, breast cancer treatment may benefit from the use of a combination of drugs in chemotherapy.

show abstract

“…In recent years, studies have indicated that curcumin is able to inhibit proliferation and survival, induce apoptotic and non-apoptotic (autophagocytosis and paraptosis) cell death, and reduce invasion and migration in various types of malignant cancer cells (7)(8)(9). Through regulation of the expression of genes associated with programmed cell death, curcumin causes a high degree of apoptosis in human breast cancer cells (10). However, few studies have been performed that investigate the underlying mechanisms of curcumin as a potential agent in breast cancer therapy.…”

Section: Introductionmentioning

confidence: 99%

Curcumin inhibits MCF‑7 cells by modulating the NF‑κB signaling pathway

et al. 2017

View full text Add to dashboard Cite

Abstract. The present study investigated the inhibitory effect of curcumin on human breast cancer MCF-7 cells and investigated the potential underlying molecular mechanisms. MCF-7 cells were cultured with curcumin at different concentrations and time points. The effects of curcumin treatment on breast cancer cell proliferation were studied using a MTT assay. Reverse transcription-quantitative polymerase chain reaction and western blot analysis were used to assess the mRNA and protein expression levels of B-cell lymphoma 2 (Bcl-2) and Bcl-2-associated X (Bax), nuclear factor-κ-light-chain-enhancer of activated B cells (NF-κB) and inhibitor of NF-κB-α (IκBα). The proliferation of MCF-7 cells in the group treated with curcumin was markedly decreased compared with the control, with the greatest inhibitory effect at a concentration of 20 µM. The expression of Bax mRNA was increased and Bcl-2 mRNA expression was decreased compared with the control. Additionally, protein expression of NF-κB and IκB was increased. The data indicate that curcumin is able to inhibit breast cancer cell proliferation, possibly by regulating the NF-κB signaling pathway.

show abstract

Curcumin in Treating Breast Cancer: A Review

Cited by 121 publications

References 93 publications

Molecular targets of curcumin in breast cancer (Review)

Molecular targets of curcumin in breast cancer (Review)

Curcumin and paclitaxel induce cell death in breast cancer cell lines

Curcumin inhibits MCF‑7 cells by modulating the NF‑κB signaling pathway

Contact Info

Product

Resources

About